Drug Information

Drug (ID: DG01565) and It's Reported Resistant Information

• Name: AZD-6482
• Synonyms: AZD6482; 1173900-33-8; AZD-6482; AZD 6482; (R)-2-(1-(7-methyl-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino)benzoic acid; CHEMBL2165191; 2-[[(1R)-1-[7-Methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]benzoic acid; UNII-78G6MP5PZ5; 2-[[(1R)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoic acid; 78G6MP5PZ5; 2-{[(1R)-1-[7-methyl-2-(morpholin-4-yl)-4-oxopyrido[1,2-a]pyrimidin-9-yl]ethyl]amino}benzoic acid; 2-({(1R)-1-[7-Methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl}amino)benzoic acid; 4urk; 2-(((1R)-1-(7-Methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido(1,2-a)pyrimidin-9-yl)ethyl)amino)benzoic acid; 2-{[(1R)-1-[7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino}benzoic acid; 2-[[(1r)-1-(7-Methyl-2-Morpholin-4-Yl-4-Oxidanylidene-Pyrido[1,2-A]pyrimidin-9-Yl)ethyl]amino]benzoic Acid; MLS006010986; GTPL8059; SCHEMBL1812377; CHEBI:91359; AOB3536; DTXSID00657619; KIN 193; KIN-193; AZD 6482 [WHO-DD]; ACT06822; EX-A1807; 2243AH; BDBM50395821; MFCD16659062; NSC799349; s1462; ZINC38628584; AKOS015935014; BCP9000355; CCG-268743; CS-0086; DB14980; NSC-799349; NCGC00263154-01; AC-32792; AS-74808; HY-10344; SMR004702788; SW219187-1; J-507622; BRD-K58772419-001-01-3; Q27074771; (-) 2-{[(1R)-1-(7-Methyl-2-morpholin-4-yl-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethyl]amino}benzoic acid; (-)-2-[[(1R)-1-[7-Methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]benzoic acid; (R)-2-((1-(7-Methyl-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethyl)amino)benzoic acid; 2-[[(1R)-1-[7-methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido[1.2-a]pyrimidin-9-yl]ethyl]amino]-benzoic acid; Benzoic acid, 2-[[(1R)-1-[7-methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]-
• Indication:
  In total 1 Indication(s)
  Thrombosis [ICD-11: DB61-GB90]; Approved; [1]
• Target: PI3-kinase beta (PIK3CB); PK3CB_HUMAN; [1]
• Formula: 5
• IsoSMILES: CC1=CN2C(=O)C=C(N=C2C(=C1)[C@@H](C)NC3=CC=CC=C3C(=O)O)N4CCOCC4
• InChI: InChI=1S/C22H24N4O4/c1-14-11-17(15(2)23-18-6-4-3-5-16(18)22(28)29)21-24-19(12-20(27)26(21)13-14)25-7-9-30-10-8-25/h3-6,11-13,15,23H,7-10H2,1-2H3,(H,28,29)/t15-/m1/s1
• InChIKey: IRTDIKMSKMREGO-OAHLLOKOSA-N
• PubChem CID: 44137675
• ChEBI ID: CHEBI:91359
• DrugBank ID: DB14980

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Prostate cancer [ICD-11: 2C82]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Phosphatase and tensin homolog (PTEN) [1]

• Molecule Alteration: Missense mutation; p.A126G (c.377C>G)
• Sensitive Disease: Prostate cancer [ICD-11: 2C82.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: PC3 cells; Prostate; Homo sapiens (Human); CVCL_0035
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: Presto blue assay; Clonogenic cell survival assay

References

• Ref 1: Discovery and functional characterization of a neomorphic PTEN mutationProc Natl Acad Sci U S A. 2015 Nov 10;112(45):13976-81. doi: 10.1073/pnas.1422504112. Epub 2015 Oct 26.